Severe Adverse Events When Osimertinib Follows Immunotherapy Severe Adverse Events When Osimertinib Follows Immunotherapy
Severe immune-related adverse events have been observed when osimrtinib was given after, but not before, immune checkpoint inhibitors in patients with advanced NSCLC.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 20, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Prophylactic cranial irradiation: Improvements for advanced NSCLC
(NRG Oncology) Prophylactic cranial irradiation (PCI), a technique used to prevent the clinical development of brain metastases, is established as a standard approach for many patients with small cell lung cancer (SCLC) after initial therapy. While studies established that PCI decreases the incidence of brain metastases for patients with locally advanced non-small cell lung cancer (LA-NSCLC), there is no established indication for its use for such NSCLC patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 18, 2019 Category: Cancer & Oncology Source Type: news

Aggressive Tx in Oligometastatic NSCLC Tied to Improved OS
(MedPage Today) -- Histology, intrathoracic disease burden, and bone metastases may predict outcomes (Source: MedPage Today Radiology)
Source: MedPage Today Radiology - March 13, 2019 Category: Radiology Source Type: news

European Commission approves Roche ’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer
Roche today announced that the European Commission has approved and granted marketing authorisation for Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab), paclitaxel and carboplatin, for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC). (Source: Roche Media News)
Source: Roche Media News - March 8, 2019 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer
Roche today announced that the European Commission has approved and granted marketing authorisation for Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab), paclitaxel and carboplatin, for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - March 8, 2019 Category: Pharmaceuticals Source Type: news

Liquid vs Tissue Biopsy in Detecting Biomarkers for Advanced NSCLC
Researchers'findings on the efficacy of a liquid biopsy test called  Guardant360 vs standard tissue biopsies will be presented at AACR 2019. (Source: CancerNetwork)
Source: CancerNetwork - March 8, 2019 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Data Bolster High-Dose Opdivo in Advanced NSCLC
(MedPage Today) -- CheckMate-384 provides " descriptive " evidence for monthly option (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 7, 2019 Category: Hematology Source Type: news

A New Task Force Promises to Cut Through Emergency Diagnostics Clutter
The diagnostics space just had a pretty significant week. From strong data to key product launches, the space saw a substantial amount of activity. It could be argued the spike in activity and timing of some of the announcements was spurred on by the reveal of a newly-formed task force comprised of FDA, Centers for Disease and Control, and the Centers for Medicare and Medicaid Services. The goal of the task force is to help make diagnostics rapidly available during public health emergencies. T2 Biosystems was the latest to make waves in the industry with news that it had obtained “Breakthrough Device&aci...
Source: MDDI - March 1, 2019 Category: Medical Devices Authors: Omar Ford Tags: IVD Regulatory and Compliance Source Type: news

It's Time to Use Liquid Biopsies for Newly Diagnosed NSCLC It's Time to Use Liquid Biopsies for Newly Diagnosed NSCLC
A liquid biopsy identifies biomarkers in patients with NSCLC at a higher rate compared with tissue genotyping and with a faster turnaround time. Is clinical practice ready for a change?Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 1, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Liquid Biopsy - Based Test IDs Biomarkers in Metastatic NSCLC
Test led to increase in number of patients with identified G7 biomarker, reduction in turnaround time (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 1, 2019 Category: Cancer & Oncology Tags: Oncology, Pathology, Pulmonology, Conference News, Source Type: news

European Panel Endorses Lorlatinib for Lung Cancer European Panel Endorses Lorlatinib for Lung Cancer
The Committee for Medicinal Products for Human Use has recommended marketing authorization for the drug for ALK-positive advanced non-small cell lung cancer.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 1, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Liquid Biopsy-Based Test IDs Biomarkers in Metastatic NSCLC
FRIDAY, March 1, 2019 -- A cell-free DNA (cfDNA) analysis using a 73-gene panel can successfully be used to identify " Guideline-7 " (G7) biomarkers in metastatic non-small cell lung cancer (mNSCLC), according to research scheduled to be presented at... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 1, 2019 Category: Pharmaceuticals Source Type: news

Could Blood Tests Replace Invasive Lung Biospies?
The so-called liquid biopsy is as effective as testing tissue samples in diagnosing advanced non-small cell lung cancer, researcher say. (Source: WebMD Health)
Source: WebMD Health - February 28, 2019 Category: Consumer Health News Source Type: news

Could Blood Tests Replace Surgical Lung Biospies?
The so-called liquid biopsy is as effective as testing tissue samples in diagnosing advanced non-small cell lung cancer, researcher say. (Source: WebMD Health)
Source: WebMD Health - February 28, 2019 Category: Consumer Health News Source Type: news

Tumor Mutation Burden in NSCLC: Tissue Versus Liquid Biopsy Tumor Mutation Burden in NSCLC: Tissue Versus Liquid Biopsy
Tumor mutation burden may be a promising tool to guide immunotherapy, yet many questions need to be answered before adoption into clinical practice.Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 28, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Liquid Biopsy Matches Tissue for NSCLC Guidance
(MedPage Today) -- Increased mutation detection rate, faster turnaround time (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 28, 2019 Category: Hematology Source Type: news

A Simple Blood Test Is as Effective as a Biopsy in Detecting Lung Cancer Mutations
This study shows that liquid biopsy is accurate and detects [markers] at the same rate as standard-of-care tissue testing of tumor tissue,” says Dr. Vassiliki Papadimitrakopoulou, professor of medicine at MD Anderson Cancer Center and lead author of the study. “This study gives us confidence that what is found in liquid biopsies really is what is found in the tumor.” (Papadimitrakopoulou serves on a number of advisory boards for pharmaceutical companies and received nominal fees as a consultant to Guardant in designing and running this trial.) Guardant360 picks up fragments of DNA that tumors shed into th...
Source: TIME: Health - February 27, 2019 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized blood test for cancer Source Type: news

Liquid biopsy as effective as tissue biopsy for non-small cell lung cancer according to MD Anderson study
(University of Texas M. D. Anderson Cancer Center) A multi-center study led by researchers at The University of Texas MD Anderson Cancer Center revealed that a liquid biopsy test called Guardant360 ® , is comparable to standard tissue biopsies in detection of guideline recommended biomarkers in advanced non-small cell lung cancer (NSCLC), has a faster turn-around time, and has the potential to support identification of more patients who can be treated with targeted therapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 27, 2019 Category: Cancer & Oncology Source Type: news

Thermo Fisher Scientific's Oncomine Dx Target Test Receives Expanded Regulatory Approval in Japan
Companion diagnostic test enables physicians to identify non-small cell lung cancer patients who may benefit from eight targeted therapies CARLSBAD, Calif., Feb. 26, 2019 -- (Healthcare Sales & Marketing Network) -- Thermo Fisher Scientific today annou... Diagnostics, Oncology, Regulatory Thermo Fisher Scientific, Oncomine Dx Target Test (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 26, 2019 Category: Pharmaceuticals Source Type: news

SBRT Proves Mettle in Early, Inoperable Lung Cancer (CME/CE)
(MedPage Today) -- Superior local control, no increase in majority toxicity, longer OS with in stage I NSCLC (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 25, 2019 Category: Primary Care Source Type: news

Stereotactic Ablative Radiotherapy Tops for Inoperable Early Non-Small-Cell Lung Cancer Stereotactic Ablative Radiotherapy Tops for Inoperable Early Non-Small-Cell Lung Cancer
Compared with standard radiotherapy, stereotactic ablative body radiotherapy (SABR) provides better local control and improved survival in patients with inoperable peripherally located stage 1 non-small-cell lung cancer (NSCLC), according to results of the CHISEL study.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - February 22, 2019 Category: Radiology Tags: Hematology-Oncology News Source Type: news

SBRT Nearly Doubles Survival for Early, Inoperable Lung Cancer
(MedPage Today) -- Establishes evidence for peripherally located stage I NSCLC (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 19, 2019 Category: Hematology Source Type: news

New Immunotherapy Clinical Trial Targets Common Mesothelioma Protein
A biotechnology company specializing in innovative cancer therapeutics has opened a clinical trial examining an immunotherapy drug targeting a protein found in 90 percent of malignant mesothelioma tumors. It is the first clinical trial to specifically study a patient population characterized by this protein expression. The target is known as VISTA, a surface protein which inhibits the immune system from working properly and allows the mesothelioma to grow. The drug is CA-170, an orally available molecule and the only anti-VISTA drug being studied today in a cancer clinical trial. And the potential could be huge. “The...
Source: Asbestos and Mesothelioma News - February 19, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

FDA grants Priority Review to Roche ’s personalised medicine entrectinib
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company ’s New Drug Applications (NDAs) and granted Priority Review for entrectinib for the treatment of adult and paediatric patients with neurotrophic tropomyosin receptor kinase (NTRK) fusion-positive, locally advanced or metastatic solid tumours who have either progressed following prior therapies or as an initial therapy when there are no acceptable standard therapies, and for the treatment of people with metastatic, ROS1-positive non-small cell lung cancer (NSCLC). (Source: Roche Media News)
Source: Roche Media News - February 19, 2019 Category: Pharmaceuticals Source Type: news

FDA grants Priority Review to Roche ’s personalised medicine entrectinib
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company ’s New Drug Applications (NDAs) and granted Priority Review for entrectinib for the treatment of adult and paediatric patients with neurotrophic tropomyosin receptor kinase (NTRK) fusion-positive, locally advanced or metastatic solid tumours who have either progressed following prior therapies or as an initial therapy when there are no acceptable standard therapies, and for the treatment of people with metastatic, ROS1-positive non-small cell lung cancer (NSCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - February 19, 2019 Category: Pharmaceuticals Source Type: news

Checkpoint Inhibitors'Not Off Table' in Autoimmune Disease Checkpoint Inhibitors'Not Off Table' in Autoimmune Disease
Patients with NSCLC and a history of autoimmune disease may, in some situations, be candidates for immune checkpoint inhibitors, says Dr Mark Kris.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 13, 2019 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

The Long-Term Benefit of Pembrolizumab in PD-L1 –Positive NSCLC
Results of the 2-year follow-up analysis of the pivotal  KEYNOTE-024 trial were recently published in the Journal of Clinical Oncology. (Source: CancerNetwork)
Source: CancerNetwork - February 12, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news

Precision Medicine Umbrella Trial Expands to Include All NSCLC Patients
The large precision medicine trial known as Lung-MAP has announced it will expand to patients with all non –small-cell lung cancers, accounting for as many as 85% of all lung cancer diagnoses in the US. (Source: CancerNetwork)
Source: CancerNetwork - February 7, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition
Small cell lung cancer (SCLC) is a recalcitrant, aggressive neuroendocrine-type cancer for which little change to first-line standard-of-care treatment has occurred within the last few decades. Unlike nonsmall cell lung cancer (NSCLC), SCLC harbors few actionable mutations for therapeutic intervention. Lysine-specific histone demethylase 1A (LSD1 also known as KDM1A) inhibitors were previously shown to have selective activity in SCLC models, but the underlying mechanism was elusive. Here, we found that exposure to the selective LSD1 inhibitor ORY-1001 activated the NOTCH pathway, resulting in the suppression of the transcr...
Source: Signal Transduction Knowledge Environment - February 5, 2019 Category: Science Authors: Augert, A., Eastwood, E., Ibrahim, A. H., Wu, N., Grunblatt, E., Basom, R., Liggitt, D., Eaton, K. D., Martins, R., Poirier, J. T., Rudin, C. M., Milletti, F., Cheng, W.-Y., Mack, F., MacPherson, D. Tags: STKE Research Articles Source Type: news

Dacomitinib for EGRF+ Lung Cancer Gets EU OK Dacomitinib for EGRF+ Lung Cancer Gets EU OK
Dacomitinib has been given a positive opinion in Europe for use in the first-line treatment of EGFR+ non-small cell lung cancer.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 1, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Dacomitinib for EGFR+ Lung Cancer Gets EU OK Dacomitinib for EGFR+ Lung Cancer Gets EU OK
Dacomitinib has been given a positive opinion in Europe for use in the first-line treatment of EGFR+ non-small cell lung cancer.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 1, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

CHMP recommends EU approval of Roche ’s Tecentriq in combination with Avastin and chemotherapy as an initial treatment for lung cancer
Roche today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab), in combination with Avastin® (bevacizumab), paclitaxel and carboplatin, for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC) . (Source: Roche Media News)
Source: Roche Media News - February 1, 2019 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche ’s Tecentriq in combination with Avastin and chemotherapy as an initial treatment for lung cancer
Roche today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab), in combination with Avastin® (bevacizumab), paclitaxel and carboplatin, for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC) . (Source: Roche Investor Update)
Source: Roche Investor Update - February 1, 2019 Category: Pharmaceuticals Source Type: news

Pfizer receives positive CHMP opinion for Vizimpro ® (dacomitinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR-activating mutations
Pfizer today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending Vizimpro® (dacomitinib) 45 mg, as monotherapy, be granted marketing authorization in the European Union (EU) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations. (Source: World Pharma News)
Source: World Pharma News - February 1, 2019 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Gefitinib, erlotinib preferred in EGFR-mutation+ NSCLC in China
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2019 Category: Drugs & Pharmacology Source Type: news

Apatinib Case Study Uncovers Potential Mesothelioma Treatment
Doctors in China may have uncovered an effective second- or third-line treatment option for patients with malignant pleural mesothelioma. Dr. RongQin Meng, an oncologist at 363 Hospital in Cheng Du, said the investigational drug Apatinib (rivoceranib) could become part of a much-needed advance in mesothelioma treatment. After first- and second-line chemotherapy combinations had failed to slow tumor growth in a 58-year-old woman, Apatinib provided a five-month progression-free survival. “I was surprised at the result,” Meng told The Mesothelioma Center at Asbestos.com. “After taking the drug, the quality o...
Source: Asbestos and Mesothelioma News - January 31, 2019 Category: Environmental Health Authors: Daniel King Source Type: news

Lung-MAP precision medicine trial expands to include more patients
(SWOG) The Lung Cancer Master Protocol (Lung-MAP), the first precision medicine trial in lung cancer supported by the National Cancer Institute (NCI), part of the National Institutes of Health, is undergoing a major expansion to include patients with all non-small cell lung cancers -- which make up about 85 percent of all lung cancer diagnoses in the US. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 29, 2019 Category: Cancer & Oncology Source Type: news

ANMI inks deal for SPECT radiopharmaceutical
Advanced Nuclear Medicine Ingredients (ANMI) has signed an agreement to license...Read more on AuntMinnie.comRelated Reading: Ga-68 PSMA-11 PET/MRI benefits prostate cancer patients New SPECT tracer targets NSCLC receptor Ga-68 PSMA-11 PET/MRI advances prostate cancer detection Study warns of PSMA-PET imaging discrepancies Gallium-labeled PET tracer could advance cancer detection (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 25, 2019 Category: Radiology Source Type: news

EMA Decision on Durvalumab in NSCLC Is'Major Cause of Concern'EMA Decision on Durvalumab in NSCLC Is'Major Cause of Concern '
Lung cancer experts say the recent decision to restrict the use of durvalumab immunotherapy to patients with high PD-L1 expression is'a lost therapeutic opportunity. 'Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 21, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

FDA accepts Roche's supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin)
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) for Tecentriq® (atezolizumab) in combination with Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) and carboplatin for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR or ALK genomic tumour aberrations. (Source: World Pharma News)
Source: World Pharma News - January 21, 2019 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Alectinib Versus Crizotinib in Treatment-Naive ALK+ NSCLC Alectinib Versus Crizotinib in Treatment-Naive ALK+ NSCLC
Compared with crizotinib, alectinib significantly delays CNS progression in patients with advanced ALK+ NSCLC.Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 21, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Mesothelioma Researchers Seek More Effectiveness from Immunotherapy
The objective-response rate was 9 percent, which included one patient with a complete response and disappearance of all tumor burden, and four patients with a partial response. Of the 48 patients whose data were assessed for change in tumor size, 24 experienced a reduction of some level. Most encouraging were the patients with a higher-level of PD-L1. They had a median overall survival of 20.2 months and a 12-month overall survival of 72.5 percent. PD-L1 presence alone, though, is not considered the only factor in how well the drug would work. Other factors such as genetic mutations of the tumor and mesothelioma cell type ...
Source: Asbestos and Mesothelioma News - January 17, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

FDA accepts Roche ’s supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) for Tecentriq® (atezolizumab) in combination with Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) and carboplatin for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR or ALK genomic tumour aberrations. (Source: Roche Media News)
Source: Roche Media News - January 17, 2019 Category: Pharmaceuticals Source Type: news

FDA accepts Roche ’s supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) for Tecentriq® (atezolizumab) in combination with Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) and carboplatin for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR or ALK genomic tumour aberrations. (Source: Roche Investor Update)
Source: Roche Investor Update - January 17, 2019 Category: Pharmaceuticals Source Type: news

Checkpoint Inhibitors: Effective in NSCLC Patients With Pre-existing Autoimmune Disease?
The results, described by an expert as “very interesting” and a “a bit surprising, " focused on the impact of autoimmune antibodies on anti –PD-1 therapy. (Source: CancerNetwork)
Source: CancerNetwork - January 15, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news

Median Survival for Stage 4 ALK-Positive NSCLC Nearly 7 Years
MONDAY, Jan. 14, 2019 -- The median overall survival (OS) from diagnosis for patients with stage IV anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) is 6.8 years, according to a study published online Dec. 29 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 14, 2019 Category: Pharmaceuticals Source Type: news

Dramatic Survival Gain Feasible in ALK+ NSCLC
(MedPage Today) -- Median of almost 7 years in single-center analysis (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 9, 2019 Category: Hematology Source Type: news

ArcherDx Seeking Broader Reach for Cancer Diagnostic
ArcherDx just got put on the fast track in getting its companion diagnostic on the market. The Boulder, CO-based company said it has been granted a Breakthrough Device Designation for its liquid biopsy and tissue specimen diagnostic application. The Breakthrough Device Designation will allow for an expedited approval pathway and would allow the company to have more frequent interactions with FDA in an effort to get to market faster. Executives from the Boulder, CO-based company found the time to speak about the test with MD+DI on Tuesday, while they were attending the very busy 37th Annual J.P. Morgan Healthcare Conference...
Source: MDDI - January 8, 2019 Category: Medical Devices Authors: Omar Ford Tags: Testing IVD Source Type: news

Boston Scientific shares tick up after Q4 prelims meet estimates | Wall Street Beat
Shares in Boston Scientific (NYSE:BSX) rose slightly this morning after the company reported preliminary results for the fourth quarter and full year of 2018 that were in-line with estimates on Wall Street. The Marlborough, Mass.-based company said it expects to report $2.56 billion in sales for the fourth quarter and $9.82 billion for the full year. In Q4, Boston Scientific’s cardiovascular business pulled in $970 million in sales, while its rhythm & neuro unit recorded $790 million in revenue. The company’s MedSurg division saw $800 million in sales, according to an SEC filing. Most of the company&rs...
Source: Mass Device - January 8, 2019 Category: Medical Devices Authors: Sarah Faulkner Tags: Business/Financial News Featured MassDevice Earnings Roundup Wall Street Beat Alphatec Boston Scientific Hologic ICON plc Integra LifeSciences NovoCure Orthofix SeaSpine Source Type: news

Veracyte Finds Ally in J & amp;J for Early Lung Cancer Detection
A new collaboration between Johnson & Johnson Innovation and Veracyte, a genomic diagnostics company, will focus on the detection of lung cancer. The long-term agreement will be used to advance the development and commercialization of novel diagnostic tests to detect lung cancer at its earliest stages, when the disease is most treatable. Under terms of the agreement, South San Francisco, CA - based Veracyte and the Lung Cancer Initiative at Johnson & Johnson, whose mission is to prevent, intercept, and cure lung cancer, will combine clinical study cohorts involving more than 5,000 patients with multiple years of cl...
Source: MDDI - January 4, 2019 Category: Medical Devices Authors: Omar Ford Tags: IVD Testing Source Type: news